A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory No
A phase 1/2 trial of Golcadomide, Rituximab, Obinutuzumab in non-hodgkin lymphoma, run by Celgene, active and no longer recruiting.
Overview
A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) is a phase 1/2 interventional study registered as NCT03930953 by Celgene, with 438 participants planned, started 2019-05-20 and due to reach its primary completion in 2027-04-07. Interventions recorded: CC-99282, Rituximab, Obinutuzumab, Tafasitamab, Valemetostat. Conditions listed: Lymphoma, Non-Hodgkin. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas
Shares Golcadomide, Obinutuzumab, Rituximab, Non-Hodgkin lymphoma (all types).
- TrialA Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma
Shares Golcadomide, Rituximab, Non-Hodgkin lymphoma (all types), Bristol Myers Squibb.
- TrialA Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Rela
Shares Golcadomide, Rituximab, Bristol Myers Squibb.
- TrialStudy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies
Shares Obinutuzumab, Rituximab, Non-Hodgkin lymphoma (all types).
- TrialA Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Pa
Shares Tafasitamab, Rituximab.
- TrialA Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Matu
Shares Obinutuzumab, Rituximab, Non-Hodgkin lymphoma (all types).
- TrialA Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
Shares Obinutuzumab, Rituximab, Non-Hodgkin lymphoma (all types).
- TrialA Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treat